Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.175E-14 | 2.254E-10 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.535E-13 | 4.458E-10 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.180E-13 | 9.103E-10 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.525E-13 | 1.366E-09 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.669E-11 | 2.137E-08 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.811E-11 | 3.400E-08 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.349E-10 | 1.399E-07 | CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.012E-10 | 4.960E-07 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.494E-10 | 4.985E-07 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 4.803E-09 | 3.268E-06 | CYP2A13, CYP2A6, CYP2D6 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.645E-08 | 9.682E-06 | CYP1A2, CYP2C19, CYP2C9 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.528E-07 | 7.736E-05 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 2.948E-07 | 1.459E-04 | CYP2A13, CYP2A6 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 8.842E-07 | 4.011E-04 | CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.237E-16 | 2.694E-12 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 8.566E-15 | 9.327E-11 | CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.631E-14 | 9.825E-11 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.152E-13 | 5.280E-11 | CYP2C9; CYP2A6; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 8.728E-13 | 5.280E-11 | CYP2C9; CYP2A6; CYP2A13; CYP2D6; CYP1A2; CYP3A4 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.792E-12 | 7.227E-11 | CYP2C9; CYP2A6; CYP2A13; CYP1A2; CYP3A4; CYP2C19 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.168E-09 | 3.533E-08 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.296E-08 | 7.975E-07 | CYP2C9; CYP2A6; CYP1A2; CYP3A4 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.983E-07 | 6.017E-06 | CYP2C9; CYP2D6; MAPK1; CYP2C19 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.510E-04 | 2.283E-03 | MAPK1; NFKB1; TSHR |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.052E-04 | 3.692E-03 | CYP2C9; CYP2A6; CYP1A2; CYP2C19; CYP3A4 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 4.317E-04 | 4.161E-03 | MAPK1; NFKB1 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.809E-04 | 3.692E-03 | CYP2A6; CYP3A4 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.108E-04 | 4.280E-03 | CYP2C9; CYP2C19 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 5.787E-04 | 4.280E-03 | MAPK1; NFKB1 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 4.317E-04 | 4.161E-03 | MAPK1; NFKB1 |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 6.883E-04 | 4.280E-03 | MAPK1; NFKB1 |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 7.075E-04 | 4.280E-03 | MAPK1; NFKB1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.470E-04 | 4.161E-03 | CYP1A2; CYP3A4 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 7.075E-04 | 4.280E-03 | MAPK1; NFKB1 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 7.075E-04 | 4.280E-03 | MAPK1; NFKB1 |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.348E-03 | 6.402E-03 | MAPK1; NFKB1 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 5.613E-04 | 4.280E-03 | MAPK1; NFKB1 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.049E-03 | 5.520E-03 | MAPK1; NFKB1 |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.625E-03 | 6.554E-03 | ACHE; MAPK1 |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 7.466E-04 | 4.302E-03 | MAPK1; NFKB1 |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.402E-03 | 6.402E-03 | MAPK1; NFKB1 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 9.802E-04 | 5.391E-03 | MAPK1; NFKB1 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.429E-03 | 6.402E-03 | MAPK1; NFKB1 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.483E-03 | 6.411E-03 | MAPK1; NFKB1 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.429E-03 | 6.402E-03 | MAPK1; NFKB1 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.596E-03 | 6.554E-03 | MAPK1; NFKB1 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.833E-03 | 6.949E-03 | MAPK1; NFKB1 |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.895E-03 | 6.949E-03 | MAPK1; NFKB1 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.567E-03 | 8.629E-03 | MAPK1; NFKB1 |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.287E-03 | 8.024E-03 | MAPK1; NFKB1 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.895E-03 | 6.949E-03 | MAPK1; NFKB1 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.788E-03 | 9.117E-03 | MAPK1; NFKB1 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.321E-03 | 8.024E-03 | MAPK1; NFKB1 |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 3.975E-03 | 1.266E-02 | MAPK1; NFKB1 |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 5.411E-03 | 1.597E-02 | MAPK1; NFKB1 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 4.524E-03 | 1.369E-02 | MAPK1; NFKB1 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 4.109E-03 | 1.275E-02 | MAPK1; NFKB1 |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 6.594E-03 | 1.900E-02 | MAPK1; NFKB1 |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 8.255E-03 | 2.323E-02 | MAPK1; NFKB1 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.440E-02 | 3.872E-02 | MAPK1; NFKB1 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.106E-02 | 3.043E-02 | MAPK1; NFKB1 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.920E-02 | 4.742E-02 | MAPK1; NFKB1 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.748E-06 | 4.750E-05 | CYP2A6; CYP1A2 |
hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 1.909E-02 | 4.742E-02 | MAPK1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.584E-02 | 4.078E-02 | MAPK1 |
hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 1.475E-02 | 3.881E-02 | MAPK1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; NFKB1; ACHE |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
NA: NA | Upper abdominal bloating | NA | ACHE |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |